HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 6 (2009), Issue 6 (June)

1. Biophysical and structural studies on the capsid protein of the human immunodeficiency virus type 1: a new drug target?
   ScientificWorldJournal, 9: 404-19. [Abstract] [Full-text]
2. Identification by high throughput screening of small compounds inhibiting the nucleic acid destabilization activity of the HIV-1 nucleocapsid protein.
   Biochimie, 91(7): 916-23. [Abstract] [Full-text]
3. Performance of OraQuick Advance Rapid HIV-1/2 Antibody Test for detection of antibodies in oral fluid and serum/plasma in HIV-1+ subjects carrying different HIV-1 subtypes and recombinant variants.
   J Clin Virol, 45(2): 150-2. [Abstract] [Full-text]
4. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.
   J Virol Methods, 159(2): 211-6. [Abstract] [Full-text]
5. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.
   J Virol Methods, 159(2): 185-93. [Abstract] [Full-text]
6. In vivo biotinylation and capture of HIV-1 matrix and integrase proteins.
   J Virol Methods, 159(2): 178-84. [Abstract] [Full-text]
7. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients.
   J Immunol, 182(12): 7389-97. [Abstract] [Full-text]
8. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages.
   J Leukoc Biol, 85(6): 1027-35. [Abstract] [Full-text]
9. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.
   Proc Natl Acad Sci U S A, 106(22): 9057-62. [Abstract] [Full-text]
10. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection.
    Proc Natl Acad Sci U S A, 106(22): 9033-8. [Abstract] [Full-text]
11. Immune reconstitution associated hypercalcemia.
    Am J Emerg Med, 27(5): 629.e1-3. [Abstract] [Full-text]
12. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
    J Trop Pediatr, 55(3): 170-6. [Abstract] [Full-text]
13. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India.
    J Trop Pediatr, 55(3): 155-9. [Abstract] [Full-text]
14. Positron emission tomography in patients suffering from HIV-1 infection.
    Eur J Nucl Med Mol Imaging, 36(7): 1176-84. [Abstract] [Full-text]
15. HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection.
    Antiviral Res, 83(1): 94-8. [Abstract] [Full-text]
16. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Antiviral Res, 83(1): 86-9. [Abstract] [Full-text]
17. Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients.
    Metabolism, 58(7): 927-33. [Abstract] [Full-text]
18. The structure of the human tRNALys3 anticodon bound to the HIV genome is stabilized by modified nucleosides and adjacent mismatch base pairs.
    Nucleic Acids Res, 37(10): 3342-53. [Abstract] [Full-text]
19. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Clin Infect Dis, 49(1): 155-9. [Abstract] [Full-text]
20. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.
    Biochem Biophys Res Commun, 385(1): 100-5. [Abstract] [Full-text]
21. Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region.
    J Theor Biol, 259(2): 229-41. [Abstract] [Full-text]
22. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.
    Virology, 389(1): 20-5. [Abstract] [Full-text]
23. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.
    J Exp Med, 206(6): 1273-89. [Abstract] [Full-text]
24. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
    J Exp Med, 206(6): 1253-72. [Abstract] [Full-text]
25. Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification.
    J Exp Med, 206(6): 1215-8. [Abstract] [Full-text]
26. Evolution of raltegravir resistance during therapy.
    J Antimicrob Chemother, 64(1): 25-32. [Abstract] [Full-text]
27. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    J Antimicrob Chemother, 64(1): 118-25. [Abstract] [Full-text]
28. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study.
    J Antimicrob Chemother, 64(1): 135-41. [Abstract] [Full-text]
29. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity.
    J Antimicrob Chemother, 64(1): 33-6. [Abstract] [Full-text]
30. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    J Antimicrob Chemother, 64(1): 126-34. [Abstract] [Full-text]
31. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
    Bioorg Med Chem Lett, 19(13): 3615-8. [Abstract] [Full-text]
32. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
    Eur J Clin Pharmacol, 65(7): 667-78. [Abstract] [Full-text]
33. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
    Proc Natl Acad Sci U S A, 106(23): 9403-8. [Abstract] [Full-text]
34. Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1.
    J Virol, 83(13): 6522-33. [Abstract] [Full-text]
35. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
    Bioorg Med Chem, 17(13): 4806-18. [Abstract] [Full-text]
36. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells.
    Mol Immunol, 46(11): 2309-16. [Abstract] [Full-text]
37. CD38 regulation in activated astrocytes: implications for neuroinflammation and HIV-1 brain infection.
    J Neurosci Res, 87(10): 2326-39. [Abstract] [Full-text]
38. Oral infectious diseases: a potential risk factor for HIV virus recrudescence?
    Oral Dis, 15(5): 313-27. [Abstract] [Full-text]
39. The cell biology of HIV-1 virion genesis.
    Cell Host Microbe, 5(6): 550-8. [Abstract] [Full-text]
40. CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract.
    Am J Reprod Immunol, 62(1): 60-71. [Abstract] [Full-text]
41. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
    Retrovirology, 6: 52. [Abstract] [Full-text]
42. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs.
    Retrovirology, 6: 51. [Abstract] [Full-text]
43. Current issues in prevention of mother-to-child transmission of HIV-1.
    Curr Opin HIV AIDS, 4(4): 319-24. [Abstract] [Full-text]
44. HIV molecular epidemiology: transmission and adaptation to human populations.
    Curr Opin HIV AIDS, 4(4): 247-52. [Abstract] [Full-text]
45. Comparative 1H NMR-based metabonomic analysis of HIV-1 sera.
    J Biomol NMR, 44(3): 127-37. [Abstract] [Full-text]
46. An African perspective on mucosal immunity and HIV-1.
    Mucosal Immunol, 2(4): 300-14. [Abstract] [Full-text]
47. Genetic and temporal dynamics of human immunodeficiency virus type 1 CRF07_BC in Xinjiang, China.
    J Gen Virol, 90: 1757-61. [Abstract] [Full-text]
48. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.
    Cytometry B Clin Cytom, 76(4): 249-60. [Abstract] [Full-text]
49. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity.
    Blood, 113(25): 6351-60. [Abstract] [Full-text]
50. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
    Blood, 113(25): 6304-14. [Abstract] [Full-text]
51. Follicular dendritic cells activate HIV-1 replication in monocytes/macrophages through a juxtacrine mechanism mediated by P-selectin glycoprotein ligand 1.
    J Immunol, 183(1): 524-32. [Abstract] [Full-text]
52. Comparison of HIV-1 prevalence and risk factors between pregnant, non-pregnant, all women and the general population in Tanzania: implications for second-generation surveillance.
    Int J STD AIDS, 20(7): 483-8. [Abstract] [Full-text]
53. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.
    J Immunol, 183(1): 661-9. [Abstract] [Full-text]
54. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
    Clin Infect Dis, 49(2): 306-9. [Abstract] [Full-text]
55. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Clin Infect Dis, 49(2): 299-305. [Abstract] [Full-text]
56. Detection of TT virus in HIV-1 exposed but uninfected individuals and in HIV-1 infected patients and its influence on CD4+ lymphocytes and viral load.
    Microb Pathog, 47(1): 33-7. [Abstract] [Full-text]
57. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines.
    Vaccine, 27(32): 4337-49. [Abstract] [Full-text]
58. Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.
    Infection, 37(3): 203-9. [Abstract] [Full-text]
59. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Infection, 37(3): 233-43. [Abstract] [Full-text]
60. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects.
    Antiviral Res, 83(2): 118-26. [Abstract] [Full-text]
61. Evaluation of the Abbott investigational use only realtime HIV-1 assay and comparison to the Roche Amplicor HIV-1 monitor test, version 1.5.
    J Mol Diagn, 11(4): 347-54. [Abstract] [Full-text]
62. Inhibition of HIV-1 replication by long-term treatment with a chimeric RNA containing shRNA and TAR decoy RNA.
    Antiviral Res, 83(2): 156-64. [Abstract] [Full-text]
63. Nef-induced CD4 endocytosis in human immunodeficiency virus type 1 host cells: role of p56lck kinase.
    J Virol, 83(14): 7117-28. [Abstract] [Full-text]
64. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
    J Virol, 83(14): 7337-48. [Abstract] [Full-text]
65. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.
    J Virol, 83(14): 7176-84. [Abstract] [Full-text]
66. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice.
    J Virol, 83(14): 7305-21. [Abstract] [Full-text]
67. Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.
    J Virol, 83(14): 7166-75. [Abstract] [Full-text]
68. Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.
    J Virol, 83(14): 7322-36. [Abstract] [Full-text]
69. Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.
    J Virol, 83(14): 7210-20. [Abstract] [Full-text]
70. Divergent Bro1 domains share the capacity to bind human immunodeficiency virus type 1 nucleocapsid and to enhance virus-like particle production.
    J Virol, 83(14): 7185-93. [Abstract] [Full-text]
71. Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation.
    J Virol, 83(14): 7049-61. [Abstract] [Full-text]
72. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
    Antimicrob Agents Chemother, 53(7): 2940-8. [Abstract] [Full-text]
73. Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.
    Antimicrob Agents Chemother, 53(7): 3156-8. [Abstract] [Full-text]
74. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Antimicrob Agents Chemother, 53(7): 2965-73. [Abstract] [Full-text]
75. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
    Antimicrob Agents Chemother, 53(7): 2816-23. [Abstract] [Full-text]
76. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.
    Lancet Infect Dis, 9(7): 409-17. [Abstract] [Full-text]
77. Cellular microRNA and P bodies modulate host-HIV-1 interactions.
    Mol Cell, 34(6): 696-709. [Abstract] [Full-text]
78. Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay.
    J Acquir Immune Defic Syndr, 51(3): 283-9. [Abstract] [Full-text]
79. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    J Acquir Immune Defic Syndr, 51(3): 290-7. [Abstract] [Full-text]
80. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy.
    J Acquir Immune Defic Syndr, 51(3): 274-82. [Abstract] [Full-text]
81. Primary HIV-1 infection among infants in sub-Saharan Africa: HPTN 024.
    J Acquir Immune Defic Syndr, 51(3): 317-22. [Abstract] [Full-text]
82. Molecular epidemiology of HIV-1 in St Petersburg, Russia: predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters.
    J Acquir Immune Defic Syndr, 51(3): 332-9. [Abstract] [Full-text]
83. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    J Med Virol, 81(8): 1323-35. [Abstract] [Full-text]
84. Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.
    J Virol Methods, 160(1): 101-10. [Abstract] [Full-text]
85. In vitro anti-HIV activity of five selected South African medicinal plant extracts.
    J Ethnopharmacol, 124(2): 182-8. [Abstract] [Full-text]
86. Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction.
    J Control Release, 137(3): 196-202. [Abstract] [Full-text]
87. X-ray structures of the hexameric building block of the HIV capsid.
    Cell, 137(7): 1282-92. [Abstract] [Full-text]
88. In vitro selection of RNA aptamers derived from a genomic human library against the TAR RNA element of HIV-1.
    Biochemistry, 48(26): 6278-84. [Abstract] [Full-text]
89. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
    J Clin Virol, 45(3): 255-8. [Abstract] [Full-text]
90. jpHMM: improving the reliability of recombination prediction in HIV-1.
    Nucleic Acids Res, 37: W647-51. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.